Mathew Blackman
Stock Analyst at Stifel
(1.41)
# 1747
Out of 5,370 analysts
69
Total ratings
54.84%
Success rate
12.97%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
INGN Inogen | Maintains: Hold | 10 7 | 6.57 | 6.54% | 12 | May 8, 2025 | |
TNDM Tandem Diabetes Care | Maintains: Buy | 60 31 | 20 | 55% | 6 | May 1, 2025 | |
PEN Penumbra | Maintains: Strong Buy | 301 318 | 261.37 | 21.67% | 2 | Apr 24, 2025 | |
CLPT ClearPoint Neuro | Maintains: Strong Buy | 19 25 | 11.6 | 115.52% | 3 | Apr 1, 2025 | |
BBNX Beta Bionics | Initiates Coverage On: Buy | 25 | 19.53 | 28.01% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Hold | 245 293 | 305.89 | -4.21% | 5 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 92 94 | 58.89 | 59.62% | 5 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 18 24 | 10.93 | 119.58% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 6 3 | 1.41 | 112.77% | 1 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 50 | n/a | n/a | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 90 100 | 83.28 | 20.08% | 11 | Aug 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 16 | 10.98 | 45.72% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 18 11 | 8.6 | 27.91% | 4 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 10 | n/a | n/a | 3 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 16 | n/a | n/a | 2 | Mar 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 64 | n/a | n/a | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 30 | n/a | n/a | 2 | Aug 26, 2020 |